Sep 2026
Abstract PR012: Encoding adaptive mechanisms of resistance to KRAS inhibition in pancreatic cancer
Clinical outcomes for pancreatic ductal adenocarcinoma (PDAC) remain poor. Although ∼90% of PDAC tumors harbor oncogenic KRAS mutations and KRAS inhibitors (KRASi) have shown clinical promise, adaptive resistance limits response depth and durability. While EGFR-mediated RAS-MAPK pathway reactivation has been impl...
Qing-Xiang Lin, Bo-Kai Song, C. Sander et al.
· Cancer Research · 0 citations